Chemotherapy for malignant glioma

References

• Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin. Oncol. 31, 595–604 (2004).
   PubMed Web of Science ®Google Scholar
• Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol. 13, 52–61 (2003).
   PubMed Web of Science ®Google Scholar
• Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/AKT/PYEN, mTOR, SHH/PTCH and angiogensisis. Expert Rev. Anticancer Ther. 4, 105–128 (2004).
   PubMedGoogle Scholar
• Walker MD, Alexander E, Hunt WE. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic astrocytoma: a co-operative clinical trial. J. Neurosurg. 49333–49343 (1978).
   Google Scholar
• Walker MD, Green SB, Byaqr DP et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323–1329 (1980).
   PubMed Web of Science ®Google Scholar
• Shapiro W, Green S, Burger P et al. A randomized comparison of intra-arterial versus intravenous BCNU with or without intravenous 5-FU for newly diagnosed patients with malignant glioma. J. Neurosurg. 76, 772–781 (1992).
   PubMed Web of Science ®Google Scholar
• Hochberg F, Pruitt A, Beck D et al. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J. Neurosurg. 63, 876–880 (1985).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of saftey and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al. A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5, 79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18, 321–324 (1990).
   PubMed Web of Science ®Google Scholar
• Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94, 815–820 (2002).
   Google Scholar
• Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental brain tumor. J. Neurooncol. 6, 300–305 (2004).
   Google Scholar
• Prados M, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procabarzine, lomustine, and vincristsine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol. 17, 3389–3395 (1999).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Blackledge GRP, Slack JA et al. Phase I trial of temozolomide (CCRG 81945: M and B 39831: NSC 362856). Br. J. Cancer 65, 287–291 (1992).
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Bleehen NM et al. Multicentre Phase II CRC trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother. Pharmacol. 40, 484–488 (1997).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide in patients with glioblastoma at first relapse. Br. J. Cancer 83, 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2763–2761 (1999).
   Google Scholar
• Stupp R, Dietrich PY, Ostermann S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 3179–3180 (2002).
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent WJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Gitti L, Taverna P et al. Importance of the DNA repair enzyme O6-alkylguanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat. Rev. 15, 279–292 (1988).
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlin T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Ostermann S, Pica A et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until death. Cancer 101, 2098–2105 (2004).
   PubMed Web of Science ®Google Scholar
• Korones DN, Benita-Weiss M, Coyle TE et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97, 1963–1968 (2003).
   PubMed Web of Science ®Google Scholar
• Chang SM, Lamborn KR, Malec M et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblstoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60, 353–367 (2004).
   PubMed Web of Science ®Google Scholar
• Bartolomei M, Mazzetta C, Kandkiewicz-Junak D et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q. J. Nucl. Med. Mol. Imaging 48, 220–228 (2004).
   PubMed Web of Science ®Google Scholar
• Gururangan S, Cokgor L, Rich JN et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncology 3, 246–250 (2001).
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the metalloprotease inhibitor marimistat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 20, 1383–1388 (2002).
   PubMed Web of Science ®Google Scholar
• Barrie M, Couprie C, Dufour G et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann. Oncol. 16, 1177–1184 (2005).
   PubMed Web of Science ®Google Scholar
• Prados MD, Yung WK, Fine HA et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortioum study. Neuro-oncology 6, 33–37 (2004).
   PubMed Web of Science ®Google Scholar
• Chua SL, Rosenthal MA, Wong SS et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro-oncology 6, 38–43 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Basso U, Reni M et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the Gruppo Italiano Co-operativo di Neuro-Oncolgica. J. Clin. Oncol. 22, 1598–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Newton H, Turowski R, Stroop T et al. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors Ann. Pharmacother. 33, 816–832 (1999).
   PubMed Web of Science ®Google Scholar
• Kumar ARV, Renaudin J, Wilson CB, Boldrey EB, Enot KJ, Levin VA. Procarbazine hydrochloride in the treatment of brain tumors. J. Neurosurg. 40, 365–371 (1974).
   PubMed Web of Science ®Google Scholar
• Franceschi E, Cavallo G, Scopece L et al. Phase II trial of carboplatin and etopopside for patients with recurrent high grade glioma. Br. J. Cancer 91, 1038–1044 (2004).
   PubMedGoogle Scholar
• Robins H, Chang SM, Prados MD et al. A Phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology 4, 109–114 (2002).
   PubMedGoogle Scholar
• Walker R, Allen J. Cisplatin in the treatment of recurrent childhood brain tumors. J. Clin. Oncol. 6, 62–55 (1985).
   Google Scholar
• Packer R, Sutton L, Goldwein J et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J. Neurosurg. 74, 433–440 (1991).
   PubMed Web of Science ®Google Scholar
• Newton H, Page M, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. J. Neurooncol. 7, 39–44 (1989).
   PubMed Web of Science ®Google Scholar
• Prados MD, Schold SC, Fine HA et al. A randomized, double-blind, placebo-controlled, Phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncology 5, 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• Billecke C, Simona C, Ashley M et al. Preclinical development and mechanisutic analysis of the polynuclear platinum compounds of the BBR series by proteomic profiling. Neuro-oncology 6, 330 (2004).
   Google Scholar
• Batchelor T, Gilbert MR, Supko JG et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97–11. Neuro-oncology 6, 21–27 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516–1525 (1999).
   PubMed Web of Science ®Google Scholar
• RTOG 0420: a Phase II study of radiation therapy plus low dose temozolomide followed by temozolomide plus irinotecan for glioblastoma multiforme.
   Google Scholar
• Gupta E, Wang X, Ramirez J et al. Modulation of glucuronidation of SN-38, the active metabolite of mirinotecan, by valproic acid and phenobarbital. Cancer Chemother. Pharmacol. 39, 440–444 (1997).
   PubMed Web of Science ®Google Scholar
• Gelmann EP. Tamoxifen for the treatment of malignancies other than breast or endometrial carcinoma. Semin. Oncol. 24, S1–65, S1–70 (1997).
   PubMedGoogle Scholar
• Baltuch GH, Dooley NP, Villemure JG, Vong VW. Protein kinase C and growth regulation of malignant gliomas. Can. J. Neurol. Sci. 22, 264–271 (1995).
   PubMedGoogle Scholar
• Couldwell W, Weiss M, DiGiorgio C et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32, 485–490 (1993).
   PubMed Web of Science ®Google Scholar
• Chamberlain M, Kormanik P. Salvage chemotherapy with tamoxifen for recurrent anaplastic astsrocytoma. Arch. Neurol. 56, 703–708 (1999).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Woods RP, Black KL, Couldwell WT, Law RE, Hinton DR. Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. J. Neurooncol. 35, 39–45 (1997).
   Google Scholar
• Pollack IF, DaRosso RC, Robertson PL et al. A Phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin. Cancer Res. 3, 1109–1115 (1997).
   PubMedGoogle Scholar
• RTOG-BR 0021. A Phase II trial of conventional radiation therapy plus high dose tamoxifen for supratentorial glioblastoma multiforme (GBM).
   Google Scholar
• Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neurooncol. 32, 253–265 (1997).
   PubMed Web of Science ®Google Scholar
• Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54, 31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Fine HA, Loeffler JS, Kyritsis A et al. A Phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc. Am. Soc. Clin. Oncol. 16, (2003) (Abstract 385).
   Google Scholar
• Chang SM, Lamborn KR, Malec M et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60, 353–357 (2004).
   PubMed Web of Science ®Google Scholar
• Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Exp. Opin. Biol. Ther. 4, 1963–1967 (2004).
   PubMed Web of Science ®Google Scholar
• Love, JM, Gudis LJ. Vitamin A, differentiation, and cancer. Curr. Opin. Cell Biol. 6, 825–831 (1994).
   PubMed Web of Science ®Google Scholar
• Yung WK, Kyritsis AP, Gleason MJ et al. Treatment of malignant gliomas with high dose 13-cis retinoic acid. Clin. Cancer Res. 2, 1931–1935 (1996).
   PubMed Web of Science ®Google Scholar
• See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-oncology 6, 253–258 (2004).
   PubMedGoogle Scholar
• Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide and 13-cis retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 21, 2305–2311 (2003).
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Saito Y, Xu R et al. Fenretinide activates caspases and induces apoptosis in gliomas. Clin. Cancer Res. 5, 2230–2235 (1999).
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Yung WK, Hess KR et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J. Clin. Oncol. 22, 4282–4289 (2004).
   PubMed Web of Science ®Google Scholar
• Sohono T, Tofilon PJ, Bruner JM, Owolabi O, Lanf FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375–4381 (2001).
   Google Scholar
• Castilla EA, Prayson RA, Kanner AA et al. Cycloxygenase-2 in oligodendroglial neoplasms. Cancer 98, 1465–1472 (2003).
   Google Scholar
• Giglio P, Levin VA. Cyclooxygenase-2 inhibitors in glioma therapy. Am. J. Ther. 11, 141–3 (2004).
   PubMedGoogle Scholar
• Reardon DA, Quinn JA, Vrendenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103, 329–338 (2005).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in glioblastoma. J. Clin. Oncol. 22, 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Peereboom D, Glen HJ et al. Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a Phase II study. J. Neurooncol. 6, (2004) (Abstract 384).
   Google Scholar
• Study JJ. HeR1/EGFR tyrosine kinase inhibitors for the treatmetn of glioblastoma multiforme. J. Neurooncol. 74, 77–86 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan D, Prados, MS, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880–887 (2005).
   Google Scholar
• Wen PY, Yung WK, Lamborn K et al. Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99–08). Neuro-oncology 6, 385a (2004).
   Google Scholar
• Cloughsey TF, Kuhn J, Wen P et al. Phase II trial of R11577 (Zarnestra) in patients with recurrent glioma not taking enzyme-inducing anti-epileptic drugs (EIAED): A North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. (2002).
   Google Scholar
• Dancey JE. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16, 1101–1114 (2002).
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar
• Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5, 292–302 (2004).
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140–3148 (1995).
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 18, 451–464, (1999).
   PubMed Web of Science ®Google Scholar
• Mishima K, Johns TG, Luwor RB et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61, 5349–5354 (2001).
   PubMed Web of Science ®Google Scholar
• Brady LW, Miyamoto C, Woo DW et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 22, 225–230 (1992).
   PubMedGoogle Scholar
• Stark-Vance VI. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Proc. World Fed. J. Neurooncology 342, 91 (2005).
   Google Scholar
• Greenfield L, Johnson VG, Youle RJ. Mutations in diptheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238, 536–539 (1987).
   Google Scholar
• Debinski W, Obiri N, Powers S et al. A novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin-13 and interleukin-4. J. Biol. Chem. 270, 16775–16780 (1995).
   PubMed Web of Science ®Google Scholar
• Fitzgerald D, Pastan I. Pseudomonas exotoxin and recombinant exotoxins derived from it. Ann. NY Acad. Sci. 685, 740–745 (1993).
   PubMed Web of Science ®Google Scholar
• Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neuro-Oncol. 65, 3–13 (2003).
   Google Scholar
• Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Acta Neurochir. Suppl. 88, 105–111 (2003).
   PubMedGoogle Scholar
• Stevens MS, Newlands ES. From triazines to triazenes to temozolomide. Eur. J. Cancer 29A, 1045–1047 (1993).
   PubMed Web of Science ®Google Scholar